Cured II ■ LENT Cancer Survivorship Research and Education

Late Effects on Normal Tissues

  • Philip Rubin
  • Louis S. Constine
  • Lawrence B. Marks
  • Paul Okunieff

Part of the Medical Radiology book series (MEDRAD)

Table of contents

  1. Front Matter
    Pages I-XII
  2. Jessica L. Hubbs, Jiho Nam, Sumin Zhou, Carol A. Hahn, Lawrence B. Marks
    Pages 7-23
  3. Thomas J. FitzGerald, Keith White, Joel Saltz, Ashish Sharma, Eliot Siegel, Marcia Urie et al.
    Pages 55-66
  4. Bharat Mittal, Avraham Eisbruch
    Pages 67-79
  5. Luigi Moretti, Eddy S. Yang, Denis E. Hallahan, Bo Lu
    Pages 81-92
  6. Karen M. Mustian, Michael Jacob Adams, Ronald G. Schwartz, Steven E. Lipshultz, Louis S. Constine
    Pages 103-115
  7. Mitchell S. Anscher, Paul R. Graves, Ross Mikkelsen, Zeliko Vujaskovic
    Pages 117-128
  8. Michael T. Milano, Jackie P. Williams, Louis S. Constine, Paul Okunieff
    Pages 129-140
  9. Back Matter
    Pages 163-175

About this book


Multimodal treatment lies at the heart of the improvement in cancer cure rates. However, the more aggressive the treatment delivery in terms of dose, time and volume for radiation and chemotherapy, the more adverse effects in normal tissues can be anticipated. Against this background, a major paradigm shift has taken place in that there is a new focus on cancer survivorship. Put another way, there has been a realization that prolongation of life must be accompanied by maintenance of the quality of life: the life worth saving must be worth living.

Common Toxicity Criteria (CTC) have been applied to assess the quality of survival of long-term cancer survivors. In the 1950s, the concept of late effects was considered unique to radiation. Yet, when the CTC were first developed more than two decades ago, they applied to acute adverse events due to chemotherapy (v1.0). Since late changes due to drugs were not recognized until years later, the initial update (v2.0) additionally incorporated only acute radiation toxicity. More recently, however, v3.0 has been designed to apply to all modalities and to encompass both early and late treatment effects. Other important developments in the United States have been the creation of the Office of Cancer Survivorship and the publication of "From Cancer Patient to Cancer Survivor: Lost in Transition" by the Institute of Medicine and the National Research Council, which has raised awareness of the many concerns facing cancer survivors.

This volume is based on the CURED II conference held in May 2007, which was attended by scientists from many leading institutions. The volume comprises 18 chapters by leading experts who address a variety of important topics relating to late treatment effects, such as mechanisms and evolution of injury, risk factors, the role of screening, options for interventions, second malignancies, and prevention. It is hoped that it will assist the reader in understanding how to prevent and treat the long-term side-effects of irradiation, thus improving the quality of life of long-term survivors of cancer.


Tumor bone brain cancer cancer treatment cell clinical trial genomics imaging lymphoma prevention radiation radiotherapy screening stem cell

Editors and affiliations

  • Philip Rubin
    • 1
  • Louis S. Constine
    • 2
  • Lawrence B. Marks
    • 3
    • 4
  • Paul Okunieff
    • 1
  1. 1.Department of Radiation OncologyUniversity of Rochester School of Medicine and DentistryRochesterUSA
  2. 2.Department of Radiation Oncology James P. Wilmot Cancer CenterUniversity of Rochester School of Medicine and DentistryRochesterUSA
  3. 3.Department of Radiation OncologyUniversity of North Carolina at Chapel HillChapel HillUSA
  4. 4.Duke University Medical CenterDurhamUSA

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 2008
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Medicine
  • Print ISBN 978-3-540-76270-6
  • Online ISBN 978-3-540-76271-3
  • Series Print ISSN 0942-5373
  • Buy this book on publisher's site